Morgan Stanley’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $468M | Sell |
2,773,467
-430,659
| -13% | -$73.6M | 0.03% | 563 |
|
|
2025
Q4 | $541M | Buy |
3,204,126
+76,978
| +2% | +$12.5M | 0.03% | 502 |
|
|
2025
Q3 | $451M | Sell |
3,127,148
-493,647
| -14% | -$67.4M | 0.03% | 558 |
|
|
2025
Q2 | $458M | Buy |
3,620,795
+817,621
| +29% | +$100M | 0.03% | 535 |
|
|
2025
Q1 | $359M | Sell |
2,803,174
-674,423
| -19% | -$91.4M | 0.03% | 588 |
|
|
2024
Q4 | $460M | Buy |
3,477,597
+316,150
| +10% | +$44.4M | 0.03% | 499 |
|
|
2024
Q3 | $460M | Buy |
3,161,447
+438,850
| +16% | +$63.5M | 0.03% | 498 |
|
|
2024
Q2 | $374M | Buy |
2,722,597
+18,043
| +0.7% | +$2.41M | 0.03% | 554 |
|
|
2024
Q1 | $371M | Sell |
2,704,554
-2,438,542
| -47% | -$333M | 0.03% | 552 |
|
|
2023
Q4 | $699M | Buy |
5,143,096
+2,211,048
| +75% | +$270M | 0.03% | 537 |
|
|
2023
Q3 | $359M | Sell |
2,932,048
-20,865
| -0.7% | -$2.65M | 0.04% | 476 |
|
|
2023
Q2 | $375M | Buy |
2,952,913
+30,107
| +1% | +$3.91M | 0.04% | 466 |
|
|
2023
Q1 | $378M | Sell |
2,922,806
-187,940
| -6% | -$24.6M | 0.04% | 447 |
|
|
2022
Q4 | $408M | Sell |
3,110,746
-598,056
| -16% | -$77.3M | 0.05% | 402 |
|
|
2022
Q3 | $434M | Buy |
3,708,802
+614,552
| +20% | +$76.3M | 0.06% | 309 |
|
|
2022
Q2 | $364M | Buy |
3,094,250
+18,639
| +0.6% | +$2.21M | 0.05% | 374 |
|
|
2022
Q1 | $401M | Sell |
3,075,611
-724,234
| -19% | -$94.3M | 0.05% | 319 |
|
|
2021
Q4 | $580M | Buy |
3,799,845
+464,222
| +14% | +$71.9M | 0.07% | 256 |
|
|
2021
Q3 | $539M | Sell |
3,335,623
-34,441
| -1% | -$5.8M | 0.07% | 248 |
|
|
2021
Q2 | $552M | Sell |
3,370,064
-2,696,319
| -44% | -$415M | 0.07% | 246 |
|
|
2021
Q1 | $913M | Sell |
6,066,383
-2,106,329
| -26% | -$335M | 0.13% | 164 |
|
|
2020
Q4 | $1.24B | Buy |
8,172,712
+1,100,694
| +16% | +$157M | 0.19% | 122 |
|
|
2020
Q3 | $958M | Buy |
7,072,018
+1,823,668
| +35% | +$247M | 0.19% | 126 |
|
|
2020
Q2 | $717M | Sell |
5,248,350
-349,498
| -6% | -$44.6M | 0.16% | 144 |
|
|
2020
Q1 | $603M | Buy |
5,597,848
+327,597
| +6% | +$37.7M | 0.16% | 135 |
|
|
2019
Q4 | $635M | Buy |
5,270,251
+1,721,446
| +49% | +$192M | 0.15% | 142 |
|
|
2019
Q3 | $353M | Sell |
3,548,805
-37,524
| -1% | -$3.93M | 0.09% | 212 |
|
|
2019
Q2 | $391M | Sell |
3,586,329
-606,558
| -14% | -$64.5M | 0.1% | 192 |
|
|
2019
Q1 | $469M | Sell |
4,192,887
-12,947
| -0.3% | -$1.42M | 0.13% | 166 |
|
|
2018
Q4 | $406M | Buy |
4,205,834
+179,724
| +4% | +$19.1M | 0.12% | 175 |
|
|
2018
Q3 | $491M | Buy |
4,026,110
+143,209
| +4% | +$16.9M | 0.12% | 167 |
|
|
2018
Q2 | $426M | Sell |
3,882,901
-47,294
| -1% | -$5.06M | 0.12% | 181 |
|
|
2018
Q1 | $420M | Buy |
3,930,195
+225,610
| +6% | +$25M | 0.12% | 172 |
|
|
2017
Q4 | $396M | Sell |
3,704,585
-1,585,399
| -30% | -$169M | 0.11% | 191 |
|
|
2017
Q3 | $588M | Sell |
5,289,984
-940,176
| -15% | -$100M | 0.18% | 125 |
|
|
2017
Q2 | $644M | Buy |
6,230,160
+906,645
| +17% | +$89.3M | 0.19% | 114 |
|
|
2017
Q1 | $520M | Buy |
5,323,515
+746,742
| +16% | +$71.5M | 0.16% | 136 |
|
|
2016
Q4 | $405M | Buy |
4,576,773
+509,739
| +13% | +$46.4M | 0.13% | 162 |
|
|
2016
Q3 | $392M | Buy |
4,067,034
+1,451,109
| +55% | +$138M | 0.13% | 157 |
|
|
2016
Q2 | $224M | Sell |
2,615,925
-1,653,513
| -39% | -$148M | 0.08% | 268 |
|
|
2016
Q1 | $371M | Sell |
4,269,438
-1,242,696
| -23% | -$111M | 0.14% | 164 |
|
|
2015
Q4 | $622M | Sell |
5,512,134
-2,306,283
| -29% | -$250M | 0.23% | 99 |
|
|
2015
Q3 | $791M | Buy |
7,818,417
+2,268,657
| +41% | +$272M | 0.29% | 58 |
|
|
2015
Q2 | $683M | Sell |
5,549,760
-548,751
| -9% | -$65.7M | 0.24% | 82 |
|
|
2015
Q1 | $698M | Buy |
6,098,511
+755,871
| +14% | +$83.4M | 0.26% | 78 |
|
|
2014
Q4 | $540M | Sell |
5,342,640
-1,683,492
| -24% | -$164M | 0.2% | 114 |
|
|
2014
Q3 | $641M | Buy |
7,026,132
+333,807
| +5% | +$29.3M | 0.25% | 82 |
|
|
2014
Q2 | $573M | Buy |
6,692,325
+844,611
| +14% | +$66.5M | 0.22% | 86 |
|
|
2014
Q1 | $461M | Buy |
5,847,714
+2,665,401
| +84% | +$222M | 0.19% | 114 |
|
|
2013
Q4 | $241M | Sell |
3,182,313
-28,122
| -0.9% | -$2M | 0.1% | 221 |
|
|
2013
Q3 | $224M | Sell |
3,210,435
-1,411,863
| -31% | -$92.5M | 0.11% | 211 |
|
|
2013
Q2 | $268M | Buy |
+4,622,298
| New | +$267M | 0.14% | 184 |
|
Other funds holding IBB
CB
Morgan Stanley's IBB Position: Q1 2026 in Review
Morgan Stanley reduced its iShares Biotechnology ETF (IBB) stake by 13% in Q1 2026, selling an estimated $73.6M and leaving 2,773,467 shares worth $468M. The position accounts for 0.03% of the portfolio, ranked #563.
Morgan Stanley first reported a position in IBB in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.24B in Q4 2020. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.
- Morgan Stanley held 2,773,467 shares of iShares Biotechnology ETF worth $468M as of Q1 2026.
- Morgan Stanley sold 430,659 iShares Biotechnology ETF shares in Q1 2026, an estimated $73.6M.
- iShares Biotechnology ETF made up 0.03% of Morgan Stanley's portfolio in Q1 2026, its #563 holding.
- Morgan Stanley first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's iShares Biotechnology ETF position peaked at $1.24B in Q4 2020.
- 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.